Engineered Bacteria with Oxygen-Dependent Promoters for Gut Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) and autoimmune disorders often involve systemic immunosuppression, which comes with side effects, and alternative therapies like fecal transfer pose safety concerns and stigma, while genetically engineered microbes that produce anti-inflammatory molecules have shown limited efficacy in patients due to viability and stability issues.
Innovation Solution
Genetically engineered bacteria that produce therapeutic molecules like butyrate are designed to be functionally silent until they reach the gut environment, where they are induced to produce anti-inflammatory and barrier-enhancing compounds, using oxygen level-dependent or reactive species-dependent promoters to ensure localized action and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic immunosuppression therapies (steroids, TNF inhibitors) are used to treat IBD, then inflammation is suppressed, but susceptibility to infectious disease and cancer increases
Solution Approach 1:
The patent applies local quality by designing bacteria that produce anti-inflammatory molecules specifically in the gut environment. The bacteria are engineered to express therapeutic proteins only under anaerobic conditions (gut-specific), delivering anti-inflammatory activity locally rather than systemically, thus treating gut inflammation without causing widespread immunosuppression
Solution Approach 2:
The bacteria utilize their own metabolic byproducts (acetate, butyrate) produced during fermentation to induce expression of anti-inflammatory molecules. This self-service mechanism allows the bacteria to autonomously sense their environment and activate therapeutic functions without external intervention, maintaining local anti-inflammatory activity while avoiding systemic effects
2Object-affected harmful factors
If fecal transfer from healthy patients is used to treat IBD, then gut barrier function is restored, but safety concerns over disease transmission and negative stigma arise
Solution Approach 1:
The patent extracts and isolates the beneficial functional components from fecal matter by using genetically engineered bacteria that produce specific anti-inflammatory molecules. This separates the therapeutic effect from the complex fecal material, eliminating transmission risks and stigma associated with fecal transfer while maintaining the restorative function
Solution Approach 2:
The engineered bacteria serve as an intermediary carrier, delivering therapeutic molecules in a controlled manner. Rather than using fecal matter directly, the bacteria act as a vector that transports and releases anti-inflammatory proteins, providing a safer and more acceptable delivery mechanism
3Object-affected harmful factors
If genetically engineered bacteria produce anti-inflammatory molecules constitutively, then therapeutic effect is achieved, but viability and stability are compromised
Solution Approach 1:
The patent implements periodic action by using conditionally controlled promoters that activate anti-inflammatory molecule production only during anaerobic growth phases. The bacteria produce therapeutic proteins periodically when environmental conditions match the gut environment, maintaining viability and stability during aerobic phases while delivering therapy during anaerobic phases
4Object-affected harmful factors
If oxygen level-dependent promoters are used to control therapeutic molecule expression, then localized action is ensured, but expression control complexity increases
Solution Approach 1:
The patent replaces complex mechanical or external control systems with a biological sensing mechanism. The oxygen level-dependent promoter uses the gut's natural anaerobic environment as a trigger, eliminating the need for external sensors, actuators, or control circuits while achieving precise spatial and temporal control of therapeutic expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacteria effectively reduce gut inflammation and enhance barrier function, potentially treating or preventing IBD and autoimmune disorders with reduced systemic side effects and improved safety profiles.
Implementation Method 1
expression of the therapeutic molecule is induced by an environmental condition, e.g., an inflammatory condition or a low oxygen condition
Implementation Method 2
butyrate is normally produced by microbial fermentation of dietary fiber and plays a central role in maintaining colonic epithelial cell homeostasis and barrier function
Data Source
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.